96 results
Page 2 of 5
8-K
EX-99.1
yjt62j a1zg3vbr
9 Nov 22
Zai Lab Announces Third Quarter 2022
4:13pm
8-K
EX-99.1
m11r9xtm7c0ckkx5dr
27 Sep 22
Entry into a Material Definitive Agreement
8:08am
8-K
EX-99.1
n5gu4ahs9tovf
9 Aug 22
Zai Lab Announces Second Quarter 2022
12:00am
8-K
EX-99.1
75s5g4g4xbbj
31 May 22
Other Events
8:51am
8-K
axrptlvvwgh9llqmd
31 May 22
Other Events
8:51am
8-K
EX-99.1
1ge19ap
10 May 22
Zai Lab Announces First Quarter 2022
4:10pm
CORRESP
70w0wxkd8vpkm24
3 May 22
Correspondence with SEC
12:00am
424B3
znsy8rqlwzo 01
30 Mar 22
Prospectus supplement
12:00am
8-K
EX-99.1
kb3j0jkpd2s8 sirok5t
1 Mar 22
Results of Operations and Financial Condition
4:17pm
8-K
EX-99.1
utjzpgzceq322cpyd
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
EX-99.1
y3pg33b5e mtql
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
8-K
EX-99.1
ayx9farv6k2wptv9
22 Nov 21
Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
7:40am
8-K
EX-99.1
kxcqr weji5u1s
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm
8-K
EX-99.2
46l8dv8
9 Nov 21
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
4:26pm